Home/Filings/4/0001209191-20-052226
4//SEC Filing

Thomas Dolca 4

Accession 0001209191-20-052226

CIK 0001510487other

Filed

Sep 27, 8:00 PM ET

Accepted

Sep 28, 5:16 PM ET

Size

12.7 KB

Accession

0001209191-20-052226

Insider Transaction Report

Form 4
Period: 2020-09-28
Thomas Dolca
Chief Medical Officer
Transactions
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2020-09-2855,0000 total
    Exercise: $67.31Exp: 2030-03-04Common Stock (55,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2020-09-28168,0570 total
    Exercise: $23.77Exp: 2028-10-22Common Stock (168,057 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2020-09-2860,0000 total
    Exercise: $35.42Exp: 2029-02-28Common Stock (60,000 underlying)
  • Disposition from Tender

    Common Stock

    2020-09-28$100.00/sh2,207$220,7000 total
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.
  • [F2]Includes 381 shares acquired under the Employment Stock Purchase Plan on September 25, 2020.
  • [F3]Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Issuer

Principia Biopharma Inc.

CIK 0001510487

Entity typeother

Related Parties

1
  • filerCIK 0001768239

Filing Metadata

Form type
4
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 5:16 PM ET
Size
12.7 KB